全文获取类型
收费全文 | 2312篇 |
免费 | 90篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 34篇 |
妇产科学 | 17篇 |
基础医学 | 239篇 |
口腔科学 | 37篇 |
临床医学 | 198篇 |
内科学 | 282篇 |
皮肤病学 | 46篇 |
神经病学 | 44篇 |
特种医学 | 102篇 |
外科学 | 1044篇 |
综合类 | 190篇 |
预防医学 | 24篇 |
眼科学 | 81篇 |
药学 | 36篇 |
2篇 | |
中国医学 | 6篇 |
肿瘤学 | 59篇 |
出版年
2024年 | 4篇 |
2023年 | 32篇 |
2022年 | 60篇 |
2021年 | 64篇 |
2020年 | 47篇 |
2019年 | 62篇 |
2018年 | 51篇 |
2017年 | 47篇 |
2016年 | 49篇 |
2015年 | 53篇 |
2014年 | 105篇 |
2013年 | 128篇 |
2012年 | 76篇 |
2011年 | 112篇 |
2010年 | 95篇 |
2009年 | 126篇 |
2008年 | 139篇 |
2007年 | 148篇 |
2006年 | 150篇 |
2005年 | 137篇 |
2004年 | 118篇 |
2003年 | 108篇 |
2002年 | 83篇 |
2001年 | 81篇 |
2000年 | 74篇 |
1999年 | 52篇 |
1998年 | 34篇 |
1997年 | 37篇 |
1996年 | 34篇 |
1995年 | 22篇 |
1994年 | 19篇 |
1993年 | 13篇 |
1992年 | 21篇 |
1991年 | 12篇 |
1990年 | 3篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1984年 | 4篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 3篇 |
排序方式: 共有2456条查询结果,搜索用时 15 毫秒
1.
2.
Miju Bae Sung Woon Chung Chung Won Lee Up Huh Min Su Kim Seung Hwan Song 《Asian journal of surgery / Asian Surgical Association》2019,42(1):235-239
Background
In Leriche syndrome, postoperative graft thrombosis remains one of the most significant clinical challenges.Methods
We reviewed 51 patients who underwent surgery for aortoiliac occlusive disease at our hospital from January 2007 to December 2014. The factors associated with graft patency were determined using the Cox proportional hazard model.Results
The 2-year prosthetic graft patency rate was 72.5%. Younger age (p = 0.017, Odd ratio (OR) = 1.112), postoperative uncontrolled hypertension (p = 0.044, OR = 3.797), and associated Trans Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease II (TASC II) D femoropopliteal lesion (p = 0.008, OR = 11.139) were significantly related factors for prosthetic graft patency after surgical repair. The existing comorbidities of the patients that indicated the need for axillo-bifemoral bypass seemed to be related to lower graft patency or other complications.Conclusions
For better graft patency after an open surgical repair of Leriche syndrome, strict postoperative hypertension control and distal run-off resolution are necessary. 相似文献3.
Pancreatic Panniculitis Associated with Allograft Pancreatitis and Rejection in a Simultaneous Pancreas–Kidney Transplant Recipient 总被引:1,自引:0,他引:1
J. L. Pike J. C. Rice R. L. Sanchez E. B. Kelly B. C. Kelly 《American journal of transplantation》2006,6(10):2502-2505
Pancreatic panniculitis is an uncommon condition that can occur in association with pancreatic disease. We present a case of pancreatic panniculitis in a female pancreas-kidney transplant recipient 5 months post-transplant. The patient was on standard immunosuppressive medications and had acute rejection of her renal allograft. The diagnosis of allograft pancreatitis and rejection presenting with pancreatic panniculitis was supported clinically, histopathologically and by laboratory and imaging data. This is the fourth case of pancreatic panniculitis occurring in a transplant recipient and the first in a simultaneous pancreas-kidney transplant recipient. It is also the first case associated with allograft rejection. Clinicians should be aware that pancreatic panniculitis may be a manifestation of underlying allograft pancreatic disease. 相似文献
4.
塞来昔布对大鼠心脏移植急性排斥反应的抑制作用 总被引:2,自引:0,他引:2
目的观察塞来昔布对大鼠心脏移植急性排斥反应的抑制作用。方法以SD大鼠为供者,Wistar大鼠为受者,进行40次腹部异位心脏移植。采用HE染色和原位末端标记(TUN EL)技术检测移植心切片,进行排斥反应的病理分级并计算移植心肌细胞的凋亡指数(AI)。结果移植心的细胞凋亡主要发生于心肌细胞;移植后第3、5d,塞来昔布治疗组心肌细胞凋亡指数分别为:1.03±0.42和3.28±2.42;对照组分别为2.35±1.51和11.35±3.46;两组比较,差异有统计学意义(P<0.001)。结论细胞凋亡是心脏移植急性排斥中组织损伤的重要机制;塞来昔布能明显抑制心肌细胞凋亡。 相似文献
5.
R. H. Wiesner B. J. Steffen K. M. David A. H. Chu R. D. Gordon J. R. Lake 《American journal of transplantation》2006,6(7):1609-1616
Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described. To investigate the risk of LAR (rejection > or = 6 months post-transplantation) data from the Scientific Registry of Transplant Recipients (SRTR) were used. We studied adult primary liver transplant recipients transplanted between June 1, 1995, and April 30, 2004, with hepatitis C virus (HCV) (n = 3356), hepatitis B virus (HBV) (n = 550) or a nonviral (n = 5740) primary cause of liver disease who were recorded as receiving continuous 3-(MMF + Tacro + steroids) versus 2-drug (Tacro + steroids) therapy for at least 6 months immediately post transplantation. Kaplan-Meier analysis showed significantly lower LAR rates 4 years post-transplant in 3- versus 2-drug HCV, HBV and nonviral disease patients. Multivariate regression confirmed 3- versus 2-drug therapy to be associated with a decreased risk of LAR. Late graft survival was significantly lower at 4 years post-transplant for patients with LAR 6-12 months post-transplantation versus patients with early rejection (78.0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes. 相似文献
6.
Options for Immunologic Support of Renal Transplantation Through the HLA and Immunology Laboratories
HLA and immunology laboratories are an integral part of clinical kidney transplant programs. They assist transplant clinicians with evaluating the immunological suitability of potential recipients for transplantation and selecting donor-recipient combinations with a low risk of immunological failure. With sophisticated new techniques becoming available for posttransplant immunological monitoring, laboratories play an increasing supporting role during posttransplant follow up. The level of precision at which immunological testing predicts clinical outcome, however, leaves room for improvement. In this article, we summarize the current state of diagnostics, discuss problems, and point out promising developments. 相似文献
7.
舌异位甲状腺的诊断与治疗 总被引:2,自引:0,他引:2
目的 :探讨舌异位甲状腺诊治方法。方法 :将我院从 1992年 10月~ 2 0 0 0年 2月收治的 18例舌异位甲状腺患者的临床资料进行总结分析 ,其中异位甲状腺全切除术 5例 ,部分切除术 3例 ,次全切除加部分带蒂移植10例。结果 :1例异位甲状腺癌行全切除术后出现甲状腺功能低下 ,部分切除术后 2例复发 ,其余 15例情况良好。结论 :术前常规B超检查、同位素扫描、细胞学检查和冰冻切片对异位甲状腺的诊断有指导意义 ;治疗上 ,患者无症状 ,异位甲状腺无恶变 ,可不予治疗 ,如果出现临床症状 ,对于副甲状腺 ,可作全切除术 ,若为迷走甲状腺 ,则行次全切除加部分带蒂移植是很好的方法 相似文献
8.
S. Aziz L. A. Soine S. L. Lewis A. P. Kruse W. C. Levy K. M. Wehe D. P. Fishbien M. D. Allen 《Transplant international》1997,10(6):446-450
A review of factors contributing to early mortality after cardiac transplantation revealed that up to 25 % of deaths were
due to primary graft dysfunction unrelated to rejection or infection. In light of this finding, evaluation of a donor heart
with regard to its suitability for transplantation takes on added importance. In an effort to screen the suitability of donor
hearts in the region covered by the Northwest Organ Procurement Agency (USA), all donors are evaluated by two-dimensional
transthoracic echocardiography as part of the initial evaluation. A total of 110 donor echocardiograms were reviewed and an
attempt was made to correlate the 30-day outcome with the parameters measured. An unexpected finding was that the presence
of left ventricular hypertrophy in the donor heart was associated with an increase in the incidence of donor heart dysfunction
compared with donors with normal echocardiographic profiles (33 % vs 3 %, P = 0.007).
Received: 12 February 1996 Received after resision: 27 June 1997 Accepted: 14 July 1997 相似文献
9.
达利珠单抗预防致敏受者肾移植后排斥反应的临床研究 总被引:6,自引:1,他引:5
目的 探讨用达利珠单抗诱导治疗预防致敏受者肾移植后急性排斥反应的有效性与安全性。方法 将 36例群体反应性抗体为 30 %~ 5 0 %的致敏受者随机分为舒莱组和对照组 ,各 18例 ,舒莱组患者于移植术前 2h和术后第 4d接受达利珠单抗 (2 0mg/次 )诱导治疗 ,两个组术后均以环孢素A、霉酚酸酯和皮质激素预防排斥反应。结果 舒莱组术后 3个月内的急性排斥反应发生率明显低于对照组 (P <0 .0 1) ;术后 2~ 4周内对照组平均每日皮质激素用量明显高于舒莱组 ;两个组人 /肾 1年存活率的差异无显著性 ;舒莱组术后肾功能的恢复较对照组快 ,但差异无显著性 ;舒莱组术后1周内CD2 5 淋巴细胞数明显降低 (P <0 .0 1) ;未观察到达利珠单抗的相关不良反应。结论 在合理筛选供受者的基础上 ,致敏受者肾移植前接受达利珠单抗诱导治疗可降低术后急性排斥反应的发生率 ,且较为安全。 相似文献
10.
Gerald S. Lipshutz Harish Mahanty Sandy Feng Ryutaro Hirose Peter G. Stock Sang-Mo Kang rew M. Posselt Chris E. Freise 《American journal of transplantation》2005,5(2):366-373
With the introduction of more potent immunosuppressive agents, rejection has decreased in simultaneous pancreas/kidney transplant (SPK) recipients. However, as a consequence, opportunistic infections have increased. The purpose of this report is to outline the course of SPK patients who developed polyomavirus-associated nephropathy (PVAN). A retrospective review of 146 consecutive SPK recipients from January 1, 1996 to December 31, 2002 was performed. Immunosuppression, rejection and development of PVAN were reviewed. Nine patients were identified. All received induction with either OKT3 or thymoglobulin. Immunosuppression included tacrolimus/cyclosporine, MMF/azathioprine and sirolimus/prednisone. Two patients were treated for kidney rejection prior to the diagnosis of PVAN. Time to diagnosis was an average of 359.3 days post-transplantation. Immunosuppression was decreased but five ultimately lost function. However, none developed pancreatic abnormalities as demonstrated by normal glucose and amylase. Two underwent renal retransplantation after PVAN diagnosis and both have normal kidney function. PVAN was the leading cause of renal loss in SPK patients in the first 2 years after transplantation and is a serious concern for SPK recipients. The pancreas, however, is spared from evidence of infection, and no pancreatic rejection occurred when immunosuppression was decreased. 相似文献